For a free, confidential legal consultation, submit your Harmful Drug Exposure injury claim or call 1-800-471-3980 now.
If you are looking for a firm that can handle Harmful Drug Exposure lawsuits, or are simply unsure if you have a case, there is no obligation to discuss your case with one of GPW's attorneys. Contact us today.
December 9th, 2005. An editorial appearing Thursday December 9, 2005 in The New England Journal of Medicine called into question the information provided by Merck for a key study about cardiovascular events caused by the arthritis drug Vioxx. The study called into question was published in November of 2000 for the VIGOR ... [More >>]
August 19th, 2005. Have a Vioxx legal claim? For a free, confidential legal consultation, Submit your Vioxx injury claim or call 1-800-471-3980 now. Of Note: Actual damages: $24.4 Million Punitive Damages: $229 Million $229 Million is the amount Merck made in sales of Vioxx from Oct. 2001, when FDA suggested the label change, to the ... [More >>]
June 9th, 2005. (Press Release) Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs' attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication. When finalized, the settlement will resolve the majority ... [More >>]
April 11th, 2005. (Press Release) The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” These drugs are approved for the treatment of schizophrenia and mania, but ... [More >>]
April 7th, 2005. (Press Release) The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the FDA web site. ... [More >>]
April 7th, 2005. (Press Release) Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs ... [More >>]
April 7th, 2005. What should I do if I am currently taking Bextra? You should speak with your doctor immediately to investigate options to discontinue Bextra and seek alternative treatments. Stevens-Johnson Syndrome In addition to cardiovascular problems, Bextra has been linked to a rare but sometimes ... [More >>]
April 7th, 2005. (Press Release) Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs ... [More >>]
December 17th, 2004. (Press Release) The FDA today released the following statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex (celecoxib): The Food and Drug Administration (FDA) learned last night from the National Cancer Institute (NCI) and Pfizer, Inc., that NCI has stopped drug administration in an ongoing clinical trial ... [More >>]
December 8th, 2004. In response to an editorial that appeared today on the New England Journal of Medicine website, Merck & Co., Inc. believes that it is important to emphasize that the company promptly and appropriately disclosed the results of the VIGOR (VIOXX Gastrointestinal Outcomes Research) study. Merck correctly communicated about the benefits ... [More >>]
You are currently browsing GPW's archives for the Harmful Drug Exposure category.
